Latest Options News

Chariot Resources has locked in a A$3.5 million secured loan facility to refinance existing debt and support its lithium exploration projects, including a major Nigerian acquisition.

WA Kaolin Limited has announced a partially underwritten pro-rata rights offer to raise up to $34.9 million, aiming to reduce debt and provide working capital to stabilise its Wickepin kaolin operations amid ongoing ASX suspension.

Iluka Resources has set the allocation price for shares issued under its 2025 final dividend DRP at $6.3449, resulting in the issuance of over 41,000 new shares to participating shareholders.

Cobre Limited has completed a $60 million capital raise to acquire majority ownership of the Sierra Atacama Copper Mine in Chile, marking its transition from explorer to producer. Meanwhile, substantial shareholder Sinomine has increased its investment in Cobre’s Botswana copper project.

Genetic Technologies Limited remains under voluntary administration while progressing a Deed of Company Arrangement and has completed the sale of its geneType business, ending the quarter with $270,000 in cash.

Perpetual Limited has updated its dividend announcement, confirming a fully unfranked ordinary dividend of 59 cents per share and setting the Dividend Reinvestment Plan price at $16.11 based on a 10-day volume weighted average price.

Xenitra Limited has secured a $30 million AUD sales agreement for Danone products with Rockcheck Group and established its Australian subsidiary as an authorised supplier, marking a major step in its China market strategy.

Alterity Therapeutics has secured encouraging regulatory feedback from the FDA on its ATH434 Phase 3 program for Multiple System Atrophy, marking a critical step towards pivotal trial initiation.

Impact Minerals has raised A$2 million through a strategic placement to advance its High Purity Alumina project and explore new industrial minerals opportunities in Western Australia.

Cynata Therapeutics has completed the 100-day primary evaluation period for its Phase 2 trial of CYP-001 in acute graft versus host disease, with results expected in June 2026. This milestone marks a critical step for the biotech’s lead cell therapy candidate in a condition with few effective treatments.

Fitzroy River Corporation has received a significant payment from Tasman Mining as part of an option exercise to acquire its royalty on the Snowy River Gold Project in New Zealand. The funds are currently held in escrow pending confirmation of key project milestones.

Rimfire Pacific Mining has exercised its option to acquire 100% of the Rabbit Trap Scandium Project, consolidating its position in a promising scandium resource in central NSW. Recent drilling results underpin the acquisition, highlighting significant mineralisation and growth potential.